Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.62 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.58 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.58 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.58 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30873972 | 1.00 | SLC13A5 (0.62) | SLC13A5PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL10836064 | 0.90 | SLC13A5 (0.59) | SLC13A5PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL22067295 | 0.87 | POLB (0.54) | SLC13A5PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL30436820 | 0.83 | HSD17B10 (0.71) | POLBHSD17B10 | |
| SCHEMBL491188 | 0.83 | HSD17B10 (0.71) | POLBHSD17B10 | |
| SCHEMBL13205866 | 0.83 | HSD17B10 (0.70) | SLC13A5NPSR1HSD17B10TSHRACHE | |
| SCHEMBL29773177 | 0.83 | HSD17B10 (0.70) | SLC13A5NPSR1HSD17B10TSHRACHE | |
| SCHEMBL14874390 | 0.83 | CYP4F2 (0.51) | SLC13A5PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL7827237 | 0.82 | NPSR1 (0.55) | FFAR4FFAR1POLBNPSR1HSD17B10 | |
| SCHEMBL7433243 | 0.82 | FFAR1 (0.50) | FFAR1POLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | NYCOMED GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | 4SC AG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-7763728-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7741488-B2 | Tetrahydropyridothiophenes as antiproliferative agents for the treatment of cancer | 4SC AG (DE) | 2010-06-22 | — | — | US | disclosed |
| US-20090257977-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | PEKARI KLAUS | 2009-10-15 | — | — | US | disclosed |
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | PEKARI KLAUS | 2009-10-08 | — | — | US | disclosed |
| EP-2051974-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | 4SC AG (DE) | 2009-04-29 | — | — | EP | disclosed |
| EP-2051983-A1 | NTETRAHYDROPYRIDOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | ALTANA PHARMA AG (DE) | 2009-04-16 | — | — | US | disclosed |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| EP-1893618-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008020045-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | 4SC AG (DE) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020024-A1 | NTETRAHYDROPYRIDOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2008-02-21 | — | — | WO | disclosed |
| EP-1851230-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006125815-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006084904-A1 | TETRAHYDROPYRIDOTHIOPHENES AS ANTRIPOLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100285149-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, CCAR2, BCL2 | SLC13A5 4529/4885PTGER1 1539/4885PTGER4 1621/4885 |
| US-20090257977-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, BCL2, CCAR2 | SLC13A5 4510/4885PTGER1 1728/4885PTGER4 1411/4885 |
| US-20090252706-A1 | Tetrahydropyridothiophenes As Antripoliferative Agents For The Treatment Of Cancer | RAB1A, RAB7A, RAB35 | SLC13A5 3189/4885PTGER1 2674/4885PTGER4 3967/4885 |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | SLC13A5 4439/4885PTGER1 1541/4885PTGER4 1425/4885 |
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | BAX, BCL2, BAD | SLC13A5 4460/4885PTGER1 1481/4885PTGER4 1471/4885 |
| US-20090098133-A1 | Tetrahydropyridothiophenes as Antiproliferative Agents for the Treatment of Cancer | MKI67, BCL2, BAX | SLC13A5 4198/4885PTGER1 1919/4885PTGER4 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.